Type 2 diabetes mellitus (T2DM) is a chronic disease involving multiple pathophysiologic defects. Therefore, multiple antidiabetic agents having different mechanisms will be beneficial for optimal glycemic control.
The combination therapy consisting the sodium-glucose co-transporter 2 (SGLT2) inhibitors and the dipeptidyl peptidase-4 (DPP-4) inhibitors complement their actions, act synergistic and provides additional properties to counter their undesired outcomes.1,2 SGLT2 inhibitors and DPP-4 inhibitors combination therapy achieve better glycemic control, weight reduction, and improve several cardio-renal outcomes without increasing the risk of hypoglycemia in T2DM patients.1,2 In this regard, Boehringer Ingelheim India and Docplexus have organized a Multi-specialty Panel discussion on 24th July 2020 from 04:00 PM IST onwards. In this webinar, an expert panel will share evolving…